These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30227048)

  • 21. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug development in serious diseases: the new "breakthrough therapy" designation.
    Woodcock J
    Clin Pharmacol Ther; 2014 May; 95(5):483-5. PubMed ID: 24747238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies.
    Avila AM; Bebenek I; Mendrick DL; Peretz J; Yao J; Brown PC
    Regul Toxicol Pharmacol; 2023 Mar; 139():105345. PubMed ID: 36746323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines.
    Poirier AF; Murphy WR
    Clin Pharmacol Ther; 2016 Dec; 100(6):603-605. PubMed ID: 27513678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status.
    Muensterman ET; Luo Y; Parker JM
    Ther Innov Regul Sci; 2019 Sep; ():2168479019874062. PubMed ID: 31558045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States.
    Kondo H; Hata T; Ito K; Koike H; Kono N
    Ther Innov Regul Sci; 2017 Jan; 51(1):51-54. PubMed ID: 30235998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview.
    Woodcock J; Buckman S; Goodsaid F; Walton MK; Zineh I
    Expert Opin Med Diagn; 2011 Sep; 5(5):369-74. PubMed ID: 23484625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status.
    Muensterman ET; Luo Y; Parker JM
    Ther Innov Regul Sci; 2020 May; 54(3):658-666. PubMed ID: 33301147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective.
    Johnson FR; Zhou M
    Value Health; 2016; 19(6):741-745. PubMed ID: 27712700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.
    Tyner KM; Zheng N; Choi S; Xu X; Zou P; Jiang W; Guo C; Cruz CN
    AAPS J; 2017 Jul; 19(4):1071-1083. PubMed ID: 28421428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of toxicological information in drug design.
    Matthews EJ; Benz RD; Contrera JF
    J Mol Graph Model; 2000 Dec; 18(6):605-15. PubMed ID: 11155316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
    Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation.
    Puthumana J; Wallach JD; Ross JS
    JAMA; 2018 Jul; 320(3):301-303. PubMed ID: 30027239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value Assessment in the Regulatory Context.
    Miller KL; Woodcock J
    Value Health; 2017 Feb; 20(2):296-298. PubMed ID: 28237213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.